Abstracts Archive - Page 2026 of 2607 - ACR Meeting Abstracts

Abstract Number: 2332 • 2015 ACR/ARHP Annual Meeting
Deriving ‘population References’ of Health Utilities for Patients with Spondyloarthritis Based on the ASAS Health Index
Ivette Essers^1,2, Mickaël Hiligsmann³, Uta Kiltz⁴, Nick Bansback⁵, Juergen Braun⁴, Désirée van der Heijde⁶ and Annelies Boonen^1,7, ¹School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, Netherlands, ²Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ³Department of Health Services Research, University of Maastricht, Maastricht, Netherlands, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, ⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁷Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: The ASAS Health Index (HI) was developed to assess the impact of spondyloarthritis (SpA) on the patients' overall function and health. Utilities are a…
Abstract Number: 2333 • 2015 ACR/ARHP Annual Meeting
Patients’ Prioritization of Patient-Centered Education and Research Topics in Rheumatic Disease
Phillip Higginbotham¹, Bernadette Johnson², Ronan O'Beirne¹, Monica Safford¹, Seth Ginsberg³, Ben Nowell⁴ and Jeffrey R. Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³CreakyJoints, New York, NY, ⁴Creaky Joints/Global Healthy Living Foundation, Upper Nyack, NY
Background/Purpose: While healthcare provider priorities often coalesce around clinical concerns, little has been done to explore which concerns are the most pressing educational concerns among…
Abstract Number: 2334 • 2015 ACR/ARHP Annual Meeting
Proof of Concept Study of the Arthritis Health Journal: An Online Tool to Promote Self-Monitoring in People with Rheumatoid Arthritis (RA)
Diane Lacaille^1,2, Erin Carruthers³, Brendan van As³, Charles H. Goldsmith^3,4, Hilary Horlock⁵, Linda Li^3,6, Anne F. Townsend^3,7, Beverly Mitchell⁸ and Paul Adam⁹, ¹Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²Rheumatology, Arthritis Research Canada, Richmond, BC, Canada, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴Health Sciences, Simon Fraser University, Burnaby, BC, Canada, ⁵Information Management / Information Technology Services, Provincial Health Services Authority, Vancouver, BC, Canada, ⁶Physical Therapy, University of British Columbia, Vancouver, BC, Canada, ⁷Occupational Science and Occupational Therapy, University of British Columbia, Vancouver, BC, Canada, ⁸Business Solutions and Collaboration, Provincial Health Services Authority, Vancouver, BC, Canada, ⁹Rheumatology Liaison, Mary Pack Arthritis Centre, Vancouver, BC, Canada
Background/Purpose: Patient passports have been used in chronic diseases to promote active involvement of patients in their care. In RA, patient monitoring of their disease…
Abstract Number: 2335 • 2015 ACR/ARHP Annual Meeting
How Much Does Fatigue Contribute to the Physician and Patient Global Estimates in Different Rheumatic Diseases? Analysis from Routine Care on a Multidimensional Health Assessment Questionnaire (MDHAQ)
Isabel Castrejón¹, Elena Nikiphorou², Ruchi Jain¹, Annie Huang¹, Joel A. Block³ and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Rheumatology, Addenbrooke's Hospital, Cambridge, United Kingdom, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Fatigue is an important problem for many patients with rheumatic diseases. Fatigue is associated with disease severity, psychological distress, and a poorer quality of…
Abstract Number: 2336 • 2015 ACR/ARHP Annual Meeting
Literature Review of Patient Reported Outcome and Health Related Quality of Life Measures for Biologic Therapies in the Management of Psoriatic Arthritis and Ankylosing Spondylitis
Steffen Jugl¹, Sultana Syeda² and Gunda Praveen², ¹BF I&D GPA, Health Economics and Outcomes Research, Novartis Pharma AG, Basel, Switzerland, ²Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India
Background/Purpose: Psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are chronic progressive conditions with substantial humanistic burden on patients and care givers. A variety of instruments,…
Abstract Number: 2337 • 2015 ACR/ARHP Annual Meeting
Depression, Bad Sleep Quality, and Functional Deficit Are Independently Associated with Persistent Fatigue in Arthritic Patients with Low Disease Activity Under Biological Dmards
Vitalie Nizeica¹, Myriam Normand², Delphine Denarie¹, Béatrice Pallot Prades¹, Philippe Collet¹, Adamah Amouzougan¹, Hervé Locrelle^1,2, Thierry Thomas^1,2 and Hubert Marotte^1,2, ¹Rheumatology Department, University Hospital of Saint-Etienne, Saint-Etienne, France, ²INSERM U1059/LBTO, Université de Lyon - Université Jean Monnet, Saint-Etienne, France
Background/Purpose: In rheumatoid arthritis (RA) or axial spondyloarthritis (axSpA) patients, fatigue has been mainly related to disease activity. Current management of rheumatic inflammatory diseases aims…
Abstract Number: 2338 • 2015 ACR/ARHP Annual Meeting
“It Was like No One Is Listening to Me”�: A Qualitative Study of the Lived Experiences of Patients with Rheumatoid Arthritis in the Setting of Patient-Physician Discordance in Assessments of Disease Activity
John M. Davis III¹, Zoran Kvrgic², Melissa M. Plagge¹, Jennifer L. Ridgeway³ and Gladys B. Asiedu³, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN
Background/Purpose: Discordance between patients with rheumatoid arthritis (RA) and their rheumatologists in their global assessments of disease activity affects around 33% of clinical encounters. The…
Abstract Number: 2339 • 2015 ACR/ARHP Annual Meeting
Impact of Abbvie’s Patient Support Program on Resource Costs in Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis
David T Rubin¹, Martha Skup², Matthew Davis³, Scott Johnson³ and Jingdong Chao², ¹University of Chicago Medicine, Chicago, IL, ²AbbVie Inc., North Chicago, IL, ³Medicus Economics, LLC, Milton, MA
Background/Purpose: AbbVie provides a Patient Support Program (PSP) to adalimumab (ADA)–treated patients to assist them with issues pertaining to medication costs, nurse support, injection training,…
Abstract Number: 2340 • 2015 ACR/ARHP Annual Meeting
Improvement in Treat to Target Serum Urate Levels: Preliminary Results from a Comparison Between Two Audits of Management
Fernando Perez-Ruiz^1,2, Mariano Andres³, Cesar Diaz-Torne⁴, Eugenio De Miguel⁵, Carmen Moragues⁶, Francisca Sivera⁷, Mercedes Jimenez⁸ and Carlos Alberto Sánchez-Piedra⁹, ¹BioCruces Health Research Institute, Baracaldo, Spain, ²Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain, ³Hospital de Alicante, Alicante, Spain, ⁴Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁵Rheumatology, University Hospital La Paz, Madrid, Spain, ⁶Rheumatology Division, Hospital Universitari Bellvitge, L´Hospitalet de Llobregat, Spain, ⁷Hospital de Elda, Alicante, Spain, ⁸Rheumatology Division, Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁹Unidad de Investigación de la Sociedad Española de Reumatología, Madrid, Spain
Background/Purpose: 1) assess the current quality of care in gout patients and 2) compare the current management with previous audit data. Methods: a second audit…
Abstract Number: 2341 • 2015 ACR/ARHP Annual Meeting
Treatment of Gout with Pharmacological Vs. Non-Pharmacological Complementary Therapy in the U.S.: An Internet Survey
Jasvinder A. Singh¹, Nipam Shah², N. Lawrence Edwards³ and H. Ralph Schumacher Jr.⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²University fo Alabama at Birmingham, Birmingham, AL, ³University of Florida, Gainsville, FL, ⁴Medicine, Rheumatology, U Penn & VA Med Ctr, Philadelphia, PA
Background/Purpose: The interplay of use of dietary supplement, diet modification and ULT adherence in gout management is not known. Therefore, we aimed to begin to…
Abstract Number: 2342 • 2015 ACR/ARHP Annual Meeting
Uric Acid-Lowering Therapy Management Among Rural Veterans Affairs Primary Care Providers
Michael Darley¹, Grant W. Cannon² and Christopher Jackson³, ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT
Background/Purpose: ACR guidelines exist for the management of gout including the use of uric acid-lowering therapy. ACR guidelines recommend routine monitoring of uric acid levels…
Abstract Number: 2343 • 2015 ACR/ARHP Annual Meeting
Impact of Colchicine Use on the Development of Incident Coronary Artery Disease
Susanna Jeurling¹, Daria Crittenden², Mark C. Fisher³, Binita Shah⁴, Steven P. Sedlis⁴, Craig T. Tenner⁵, Svetlana Krasnokutsky Samuels⁶ and Michael H. Pillinger⁷, ¹Division of Rheumatology, NYU School of Medicine, New York, NY, ²Rheumatology, NYU-HJD, New York, NY, ³Rheumatology, New York Univ-HJD, New York, NY, ⁴NYU School of Medicine, Division of Cardiology, New York, NY, ⁵Medicine, NYU School of Medicine, New York, NY, ⁶NYU School of Medicine, Division of Rheumatology, New York, NY, ⁷Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY
Background/Purpose: Patients with gout experience both inflammation and increased risk of cardiovascular disease (CVD). Studies suggest that colchicine reduces myocardial infarction (MI) risk, but whether…
Abstract Number: 2344 • 2015 ACR/ARHP Annual Meeting
A 3-Year Follow-up Study of Canakinumab in Frequently Flaring Gouty Arthritis Patients, Contraindicated, Intolerant, or Unresponsive to Nonsteroidal Anti-Inflammatory Drugs and/or Colchicine
Naomi Schlesinger¹, Thomas Bardin^2,3, Mark Bloch⁴, Karine Lheritier⁵, Uwe Machein⁵, Guido Junge⁵, Alexander So⁶ and Rieke Alten⁷, ¹Medicine, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, ²Hopital Lariboisière, Paris, France, ³Rhumatology Departement, Hôpital Lariboisière, Paris, France, ⁴Holdsworth House Medical Practice, Sydney, Australia, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶CHU Vaudois, University of Lausanne, Lausanne, Switzerland, ⁷Charité Univ Medicine, Berlin, Germany
Background/Purpose: Although anti-inflammatory drugs such as nonsteroidal anti-inflammatory drugs and colchicine are the recommended treatment options for pain and inflammation management in patients (pts) with…
Abstract Number: 2345 • 2015 ACR/ARHP Annual Meeting
Canakinumab Liquid Formulation in Acute Gouty Arthritis Patients: Long-Term Safety and Efficacy Results from a 36-Week Extension Study
Prashanth Sunkureddi¹, Rüdiger Moericke², Edith Tóth³, Jacques P Brown⁴, Uwe Machein⁵, Karine Lheritier⁵, Guido Junge⁵ and Alan J Kivitz⁶, ¹Clear Lake Rheumatology, Nassau Bay, TX, ²Institut für Präventive Medizin & Klinische Forschung GbR, Magdeburg, Germany, ³Flór Francis Hospital Rheumatology Department, Kistarcsa, Hungary, ⁴Centre Hospitalier de l'Université Laval (CHUL), Quebec City, QC, Canada, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Patients with gouty arthritis (GA) experience frequent flares with pain and inflammation. The limited available treatment options and typical comorbidities warrant effective alternative treatments1.…
Abstract Number: 2346 • 2015 ACR/ARHP Annual Meeting
Rebamipide Suppresses Monosodium Urate Crystal-Induced Interleukin-1b Production through Regulation of Oxidative Stress and Caspase-1 in THP-1 Cells
Jung-Yoon Choe¹, Minyoung Her² and Seong-Kyu Kim³, ¹Division of Rheumatology, Daegu Catholic University Medical Center, Daegu, South Korea, ²Busan Paik Hospital, Inje University, Busan, South Korea, ³Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, South Korea
Background/Purpose: This study investigated the effect of rebamipide on activation of NLRP3 inflammasome and reactive oxygen species (ROS) in monosodium urate (MSU) crystal-induced interleukin-1b (IL-1b)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].